The global Etoricoxib market is projected to grow substantially from USD 123.21 Million in 2025 to USD 245.94 Million by 2031, demonstrating a 12.21% CAGR. Etoricoxib, a selective COX-2 inhibitor non-steroidal anti-inflammatory drug (NSAID), provides symptomatic relief for various conditions including osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and gout. This market expansion is primarily driven by the increasing global incidence of musculoskeletal disorders and a growing geriatric population, both necessitating effective, long-term pain management solutions with a lower gastrointestinal toxicity profile than conventional NSAIDs. Musculoskeletal conditions already account for 17.1% of global years lived with disability in 2024, creating consistent demand for Etoricoxib in regions where it is authorized.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 123.21 Million
Market Size 2031	USD 245.94 Million
CAGR 2026-2031	12.21%
Fastest Growing Segment	Direct
Largest Market	Asia Pacific

Market Driver

The primary driver for the Etoricoxib market is the rising global prevalence of chronic musculoskeletal disorders such as osteoarthritis and rheumatoid arthritis, which creates a significant demand for effective anti-inflammatory therapies. These conditions often require prolonged pain management, intensifying the need for selective COX-2 inhibitors like Etoricoxib in approved markets. For instance, global rheumatoid arthritis cases are anticipated to increase by approximately 80.2% from 2020 levels by 2050, directly boosting the consumption of Etoricoxib. Additionally, the expanding geriatric population, which constituted 10.3% of individuals aged 65 and older in 2024, contributes significantly to market growth due to their susceptibility to chronic musculoskeletal issues and the benefit of Etoricoxib's reduced risk of gastrointestinal bleeding compared to traditional NSAIDs, as evidenced by a 7% sales increase for Arcoxia in Q1 2024, particularly in the Asia Pacific region.

Market Challenge

The most significant challenge impeding the Global Etoricoxib Market's growth is the strict regulatory exclusion imposed by the US Food and Drug Administration (FDA) due to concerns about cardiovascular thrombotic risks. This lack of FDA approval effectively prevents Etoricoxib from accessing the United States, which is the world's largest and most lucrative pharmaceutical market. Consequently, manufacturers are forced to limit their commercial operations primarily to European and Asia-Pacific regions, thereby severely capping the drug's overall revenue potential. With North America alone accounting for 54.8% of estimated global pharmaceutical sales in 2024, this regulatory barrier structurally constrains Etoricoxib's growth trajectory, regardless of its efficacy or demand in authorized territories.

Market Trends

Two notable trends are reshaping the Etoricoxib market. Firstly, there is a proliferation of Fixed-Dose Combinations (FDCs) that integrate muscle relaxants and opioids, aiming to enhance therapeutic efficacy through multimodal analgesia, improve patient compliance, and reduce the burden of multiple pills. Pharmaceutical companies are developing biphasic and combination therapies, such as Etoricoxib paired with Tramadol or Thiocolchicoside, to provide superior relief for acute musculoskeletal conditions, exemplified by a study on an Etoricoxib-Tramadol biphasic tablet demonstrating equivalent efficacy with simplified dosing. Secondly, a surge in generic manufacturing and exports from Asia-Pacific hubs, particularly India and China, is transforming the global supply chain. These regions are leveraging cost-efficient production capabilities to become the primary suppliers of non-steroidal anti-inflammatory formulations for markets that accept Etoricoxib, meeting demand in Europe, Latin America, and the Middle East, as underscored by India's pharmaceutical exports reaching USD 30.47 billion in fiscal year 2024-25.

Key Market Players

Merck & Co., Inc.
Sun Pharmaceutical Industries Limited
Dr. Reddy's Laboratories Limited
Cipla Limited
Lupin Limited
Torrent Pharmaceuticals Limited
Zydus Lifesciences Limited
Aurobindo Pharma Limited
Teva Pharmaceutical Industries Ltd.
Alkem Laboratories Limited

Report Scope

In this report, the Global Etoricoxib Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Etoricoxib Market, By Sales Channel

Direct
Indirect

Etoricoxib Market, By End Use

Osteoarthritis
Rheumatoid Arthritis
Ankylosing Spondylitis
Acute Gouty Arthritis
Others

Etoricoxib Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Etoricoxib Market.

Available Customizations:

Global Etoricoxib Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Etoricoxib Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Sales Channel (Direct, Indirect)
- 5.2.2. By End Use (Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Acute Gouty Arthritis, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2025)
5.3. Market Map

6. North America Etoricoxib Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Sales Channel
- 6.2.2. By End Use
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Etoricoxib Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Sales Channel
    - 6.3.1.2.2. By End Use
- 6.3.2. Canada Etoricoxib Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Sales Channel
    - 6.3.2.2.2. By End Use
- 6.3.3. Mexico Etoricoxib Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Sales Channel
    - 6.3.3.2.2. By End Use

7. Europe Etoricoxib Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Sales Channel
- 7.2.2. By End Use
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Etoricoxib Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Sales Channel
    - 7.3.1.2.2. By End Use
- 7.3.2. France Etoricoxib Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Sales Channel
    - 7.3.2.2.2. By End Use
- 7.3.3. United Kingdom Etoricoxib Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Sales Channel
    - 7.3.3.2.2. By End Use
- 7.3.4. Italy Etoricoxib Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Sales Channel
    - 7.3.4.2.2. By End Use
- 7.3.5. Spain Etoricoxib Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Sales Channel
    - 7.3.5.2.2. By End Use

8. Asia Pacific Etoricoxib Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Sales Channel
- 8.2.2. By End Use
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Etoricoxib Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Sales Channel
    - 8.3.1.2.2. By End Use
- 8.3.2. India Etoricoxib Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Sales Channel
    - 8.3.2.2.2. By End Use
- 8.3.3. Japan Etoricoxib Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Sales Channel
    - 8.3.3.2.2. By End Use
- 8.3.4. South Korea Etoricoxib Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Sales Channel
    - 8.3.4.2.2. By End Use
- 8.3.5. Australia Etoricoxib Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Sales Channel
    - 8.3.5.2.2. By End Use

9. Middle East & Africa Etoricoxib Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Sales Channel
- 9.2.2. By End Use
- 9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Etoricoxib Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Sales Channel
    - 9.3.1.2.2. By End Use
- 9.3.2. UAE Etoricoxib Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Sales Channel
    - 9.3.2.2.2. By End Use
- 9.3.3. South Africa Etoricoxib Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Sales Channel
    - 9.3.3.2.2. By End Use

10. South America Etoricoxib Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Sales Channel
- 10.2.2. By End Use
- 10.2.3. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Etoricoxib Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Sales Channel
    - 10.3.1.2.2. By End Use
- 10.3.2. Colombia Etoricoxib Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Sales Channel
    - 10.3.2.2.2. By End Use
- 10.3.3. Argentina Etoricoxib Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Sales Channel
    - 10.3.3.2.2. By End Use

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Etoricoxib Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Merck & Co., Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Sun Pharmaceutical Industries Limited
15.3. Dr. Reddy's Laboratories Limited
15.4. Cipla Limited
15.5. Lupin Limited
15.6. Torrent Pharmaceuticals Limited
15.7. Zydus Lifesciences Limited
15.8. Aurobindo Pharma Limited
15.9. Teva Pharmaceutical Industries Ltd.
15.10. Alkem Laboratories Limited

16. Strategic Recommendations

17. About Us & Disclaimer

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ

SELECT AN OPTION